Skip to main content
Figure 3 | Molecular Cancer

Figure 3

From: Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo

Figure 3

Collagen IV expression in xenograft tumors and gallbladder cancer tissues, Collagen IV prevents the diffusion of myxoma virus in gallbladder cancer tissues. A, B. (A) The western blot of samples from tissue extracted from tumors that were probed with an antibody to collagen I, collagen IV, or ß-actin. (B) The histogram represents the relative densitometry levels revealed by the western blot (*, P < 0.05 compared with the U251 group). C, D. (C) The immunohistochemistry results showing collagen IV distribution in xenograft tumors formed by implanting GBC-SD, SGC-996, or U251 cells and the (D) H-Scores (*, P < 0.05 compared with U251 group). E, F. (E) The immunohistochemistry results showing collagen IV distribution in clinical samples of gallbladder cancer or glioma and the (F) H-Scores. G. Virus diffusion across a collagen matrix barrier. In the top row, the control well allowed free diffusion of the GFP-expressing MYXV. In the second row, collagen IV markedly reduced the proportion of viruses that migrated past the barrier. In the bottom row, the proportion of vMyx-gfp–infected cells was restored to control levels by pre-treatment with collagenase. H. The percentage of GFP-positive areas in the examined field (*, P < 0.05 compared with the collagen IV group).

Back to article page

Molecular Cancer

ISSN: 1476-4598